The Experts below are selected from a list of 75 Experts worldwide ranked by ideXlab platform
Stacey R Long - One of the best experts on this subject based on the ideXlab platform.
-
the impact of nebulized levalbuterol on health care payments for elderly asthma and chronic obstructive pulmonary disease patients in medicaid plans
Disease Management & Health Outcomes, 2007Co-Authors: Ronald J. Ozminkowski, Shaohung Wang, Stacey R LongAbstract:Objective: To compare health expenditures among elderly Medicaid patients with asthma or chronic obstructive pulmonary disease (COPD) who used either nebulized levalbuterol (Levosalbutamol) or racemic albuterol (salbutamol) for bronchodilation.
-
The Impact of Nebulized Levalbuterol on Health Care Payments for Elderly Asthma and Chronic Obstructive Pulmonary Disease Patients in Medicaid Plans
2026Co-Authors: Ronald J. Ozminkowski, Shaohung Wang, Stacey R LongAbstract:Objective: To compare health expenditures among elderly Medicaid patients with asthma or chronic obstructive pulmonary disease (COPD) who used either nebulized levalbuterol (Levosalbutamol) or racemic albuterol (salbutamol) for bronchodilation. Methods: A retrospective, quasi-experimental study was conducted. Trends over time in total medical expenditures and disease-specific expenditures were compared for levalbuterol versus racemic albuterol patients. Differences in these trends were estimated by conducting generalized estimating equation regression analyses of difference-in-difference regression models. Prior to comparing levalbuterol and racemic albuterol users, these models controlled for their differences in demographics, reason for Medicaid eligibility, location, health-plan type, co-morbidities, severity of asthma or COPD, the use of other medications, and the receipt of influenza or pneumonia inoculations. Several sensitivity analyses were also conducted to estimate the reliability of the results, as related to inclusion criteria (e.g. days of therapy), regression methods, or to conduct separate analyses for asthma and COPD patients. Results: When asthma and COPD patients were pooled, every analysis of total healthcare expenditures showed large, statistically significant savings associated with levalbuterol use. These savings ranged from $US1167 to $US1792 per patient over a 6-month period, depending on inclusion criteria or statistical methods. When the analyses were separated by disease, a focus on total health expenditures still favored levalbuterol and the savings associated with levalbuterol use were about twice as high per patient for COPD patients ($US2490) as they were for asthma patients ($US1122). A focus on disease-related expenditures showed a statistically significant loss of approximately $US853 per patient for levalbuterol users who had asthma (p = 0.0031) but a statistically significant saving of approximately $US967 for COPD patients who used levalbuterol (p = 0.0031). Conclusions: A focus on total medical expenditures showed that the added costs of using levalbuterol were more than offset by reductions in other types of healthcare expenditures. Savings were higher for COPD patients than for asthma patients. A focus on disease-related expenditures showed savings for COPD patients who used levalbuterol, but results for asthma patients favored racemic albuterol.Asthma, Chronic-obstructive-pulmonary-disease, Co-payment, Elderly, Levosalbutamol, Salbutamol
Ronald J. Ozminkowski - One of the best experts on this subject based on the ideXlab platform.
-
the impact of nebulized levalbuterol on health care payments for elderly asthma and chronic obstructive pulmonary disease patients in medicaid plans
Disease Management & Health Outcomes, 2007Co-Authors: Ronald J. Ozminkowski, Shaohung Wang, Stacey R LongAbstract:Objective: To compare health expenditures among elderly Medicaid patients with asthma or chronic obstructive pulmonary disease (COPD) who used either nebulized levalbuterol (Levosalbutamol) or racemic albuterol (salbutamol) for bronchodilation.
-
The Impact of Nebulized Levalbuterol on Health Care Payments for Elderly Asthma and Chronic Obstructive Pulmonary Disease Patients in Medicaid Plans
2026Co-Authors: Ronald J. Ozminkowski, Shaohung Wang, Stacey R LongAbstract:Objective: To compare health expenditures among elderly Medicaid patients with asthma or chronic obstructive pulmonary disease (COPD) who used either nebulized levalbuterol (Levosalbutamol) or racemic albuterol (salbutamol) for bronchodilation. Methods: A retrospective, quasi-experimental study was conducted. Trends over time in total medical expenditures and disease-specific expenditures were compared for levalbuterol versus racemic albuterol patients. Differences in these trends were estimated by conducting generalized estimating equation regression analyses of difference-in-difference regression models. Prior to comparing levalbuterol and racemic albuterol users, these models controlled for their differences in demographics, reason for Medicaid eligibility, location, health-plan type, co-morbidities, severity of asthma or COPD, the use of other medications, and the receipt of influenza or pneumonia inoculations. Several sensitivity analyses were also conducted to estimate the reliability of the results, as related to inclusion criteria (e.g. days of therapy), regression methods, or to conduct separate analyses for asthma and COPD patients. Results: When asthma and COPD patients were pooled, every analysis of total healthcare expenditures showed large, statistically significant savings associated with levalbuterol use. These savings ranged from $US1167 to $US1792 per patient over a 6-month period, depending on inclusion criteria or statistical methods. When the analyses were separated by disease, a focus on total health expenditures still favored levalbuterol and the savings associated with levalbuterol use were about twice as high per patient for COPD patients ($US2490) as they were for asthma patients ($US1122). A focus on disease-related expenditures showed a statistically significant loss of approximately $US853 per patient for levalbuterol users who had asthma (p = 0.0031) but a statistically significant saving of approximately $US967 for COPD patients who used levalbuterol (p = 0.0031). Conclusions: A focus on total medical expenditures showed that the added costs of using levalbuterol were more than offset by reductions in other types of healthcare expenditures. Savings were higher for COPD patients than for asthma patients. A focus on disease-related expenditures showed savings for COPD patients who used levalbuterol, but results for asthma patients favored racemic albuterol.Asthma, Chronic-obstructive-pulmonary-disease, Co-payment, Elderly, Levosalbutamol, Salbutamol
Shaohung Wang - One of the best experts on this subject based on the ideXlab platform.
-
the impact of nebulized levalbuterol on health care payments for elderly asthma and chronic obstructive pulmonary disease patients in medicaid plans
Disease Management & Health Outcomes, 2007Co-Authors: Ronald J. Ozminkowski, Shaohung Wang, Stacey R LongAbstract:Objective: To compare health expenditures among elderly Medicaid patients with asthma or chronic obstructive pulmonary disease (COPD) who used either nebulized levalbuterol (Levosalbutamol) or racemic albuterol (salbutamol) for bronchodilation.
-
The Impact of Nebulized Levalbuterol on Health Care Payments for Elderly Asthma and Chronic Obstructive Pulmonary Disease Patients in Medicaid Plans
2026Co-Authors: Ronald J. Ozminkowski, Shaohung Wang, Stacey R LongAbstract:Objective: To compare health expenditures among elderly Medicaid patients with asthma or chronic obstructive pulmonary disease (COPD) who used either nebulized levalbuterol (Levosalbutamol) or racemic albuterol (salbutamol) for bronchodilation. Methods: A retrospective, quasi-experimental study was conducted. Trends over time in total medical expenditures and disease-specific expenditures were compared for levalbuterol versus racemic albuterol patients. Differences in these trends were estimated by conducting generalized estimating equation regression analyses of difference-in-difference regression models. Prior to comparing levalbuterol and racemic albuterol users, these models controlled for their differences in demographics, reason for Medicaid eligibility, location, health-plan type, co-morbidities, severity of asthma or COPD, the use of other medications, and the receipt of influenza or pneumonia inoculations. Several sensitivity analyses were also conducted to estimate the reliability of the results, as related to inclusion criteria (e.g. days of therapy), regression methods, or to conduct separate analyses for asthma and COPD patients. Results: When asthma and COPD patients were pooled, every analysis of total healthcare expenditures showed large, statistically significant savings associated with levalbuterol use. These savings ranged from $US1167 to $US1792 per patient over a 6-month period, depending on inclusion criteria or statistical methods. When the analyses were separated by disease, a focus on total health expenditures still favored levalbuterol and the savings associated with levalbuterol use were about twice as high per patient for COPD patients ($US2490) as they were for asthma patients ($US1122). A focus on disease-related expenditures showed a statistically significant loss of approximately $US853 per patient for levalbuterol users who had asthma (p = 0.0031) but a statistically significant saving of approximately $US967 for COPD patients who used levalbuterol (p = 0.0031). Conclusions: A focus on total medical expenditures showed that the added costs of using levalbuterol were more than offset by reductions in other types of healthcare expenditures. Savings were higher for COPD patients than for asthma patients. A focus on disease-related expenditures showed savings for COPD patients who used levalbuterol, but results for asthma patients favored racemic albuterol.Asthma, Chronic-obstructive-pulmonary-disease, Co-payment, Elderly, Levosalbutamol, Salbutamol
Ganeswar Mohanta - One of the best experts on this subject based on the ideXlab platform.
-
Stability-indicating RP-HPLC method for simultaneous estimation of Levosalbutamol sulfate and theophylline in combined dosage form
Universidade de São Paulo, 2013Co-Authors: Sagar Suman Panda, Bera Venkata Varaha Ravi Kumar, Ganeswar MohantaAbstract:A novel, simple, accurate and precise RP-HPLC method for simultaneous determination of Levosalbutamol sulfate and theophylline has been developed and validated. Separation was achieved on a Phenomenex; C18 column (250 mm × 4.6 mm i.d., 5 µm) using methanol: 10 mM TBAHS(tetrabutyl ammonium hydrogen sulfate) (50:50, v/v) as mobile phase at flow rate of 1.0 mL.min-1. The UV detection wavelength was 274 nm. The linearity is obeyed over a concentration range of 0.5-150 µg.mL-1 with correlation coefficient of 0.999 for both the drugs. The proposed method was validated by determining accuracy, precision, stability and system suitability parameters. The method was found to be robust. Specificity of the method was determined by subjecting the drugs to various stress conditions like acid, alkali, oxidation, thermal and photolytic degradation. The method was used successfully for the simultaneous determination of Levosalbutamol sulfate and theophylline in syrup dosage form
P., Uma Devi - One of the best experts on this subject based on the ideXlab platform.
-
DRUG UTILIZATION PATTERN IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE INPATIENTS AT A TERTIARY CARE HOSPITAL
'Innovare Academic Sciences Pvt Ltd', 2015Co-Authors: Unni Aswathy, Jayaprakash, Akshaya K, Mc. Yadukrishnan, P., Uma DeviAbstract:Objective: Drug utilization studies provide useful insights into the current prescribing practices. In view of this, the present study was designed to establish the drug utilization pattern in hospitalized chronic obstructive pulmonary disease (COPD) patients.Methods: In this retrospective study, all patient data relevant to the study were obtained by examination of patient's medical records and hospital information system.Results: A total of 237 patients with acute exacerbation were evaluated. The population predominantly consisted of males (92.4%) and most of the patients were in the age group of 61 to 70 y (39.7%). Cough, sputum production and dyspnea were observed in 88.2%, 80.6% and 37.6% patients, respectively. Hypertension (49.4%) was the most common co-morbidity. Candida albicans (16%) and Pseudomonas aeruginosa (4.6%) were the most common microorganisms isolated from sputum samples. Majority of the patients were on multidrug therapy during both hospital stay (98.7%) and at the time of discharge (99.6%). During hospital stay, the most commonly prescribed drugs were ipratropium (91.6%) and Levosalbutamol (88.2%); antibiotics and systemic corticosteroids were received by 96.2% and 83.1% patients, respectively. At discharge, antibiotics, inhaled corticosteroids, methyl xanthines, long acting beta-2 agonist and tiotropium were received by 94.1%, 93.7%, 92.4%, 86.1% and 56.5% patients, respectively.Conclusion: The prescribing trend observed at our hospital appears to be in concordance with the current guidelines for the management of COPD patients.Â